Research to combat diabetes using genetics and novel technologies

Completed

Conditions: Healthy
Diabetes

Registration Number: CTRI/2017/09/009909

Lead Sponsor: Madras Diabetes Research Foundation

Brief Summary: Diabetesis a major problem in India with 1 in 12 people affected amounting to 69million with diabetes currently. Majorityof the studies on how diabetes develops, how patients respond to medicationsand the determinants of medical complications that arise are from whiteEuropean ancestry populations despite the fact that diabetes in Europeans isvery different to diabetes in Indian-Asians. There is a need for a large in-depth study of the causes andconsequences of diabetes in India in order to identify patient strata in apopulation-specific way. The unitcommands access to two of the most advanced type 2 diabetes management systemsin the world: the Scottish Care Information-Diabetes (SCI-DC), which provides asophisticated shared electronic patient record for every individual with type 2diabetes in Scotland (n=250K) and the DrMohanâ€™s Specialities Diabetes Centres (DMDSC). This unit will integrateclinical, retinal image and molecular information to achieve personalizeddiabetes treatment in India, in particular to provide a low-cost, agile andsustainable solution for telemedicine outreach to the rural population India.

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: All

Target Recruitment: 30000

Inclusion Criteria

Type 2 Diabetes Cohort Study Those who have at least 4 or more follow ups in the hospital Cross sectional study Individuals aged â‰¥ 20 years Willing to participate in the study Usual resident of the selected locality.

Exclusion Criteria

Known cases of type 1 diabetes Diabetes secondary to other causes eg.chronic pancreatitis Under 20 years of age or over 80 years of age Refused consent.

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To provide a low cost, agile and sustainable solution supported by telemedicine for outreach to the poorest populations in rural India.	4 years
To determine genomic signatures of diabetes subtypes specific to the Indian sub-continent including those defined by therapeutic response to established anti-diabetic medications.	4 years

Secondary Outcome Measures

Name	Time	Method
To establish genetic determinants of genetic complications	3 years

Trial Locations

Locations (1): Madras Diabetes Research Foundation
🇮🇳
Chennai, TAMIL NADU, India
Madras Diabetes Research Foundation
🇮🇳Chennai, TAMIL NADU, India
Dr V Mohan
Principal investigator
drmohans@diabetes.ind.in